

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Sep 2026

comparison of memantine and ritalin in the treatment of children with ADHD

Protocol summary

Summary

The aim of this randomized double blind clinical trial is comparison of Memantine and Methylphenidate in the treatment of children with ADHD. In this study, 40 patients with attention deficit disorder - hyperactivity that are having inclusion criteria such as diagnostic criteria, age range and not using any psychiatric drugs and exclusion criteria such as having mental retardation; having any psychiatric disorders, Seizure, heart disease, allergic history to Memantine and etc, were randomly divided into intervention or control groups. Patients in the intervention group will receive Memantine and in the control group will receive Methylphenidate. In this study, we compare the effectiveness of Memantine and Methylphenidate drugs.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201205157462N7**

Registration date: **2012-06-01, 1391/03/12**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2012-06-01, 1391/03/12

Registrant information

Name

Mohammad Reza Mohammadi

Name of organization / entity

Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 5541 3540

Email address

pprc@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Tehran University of Medical Sciences

Expected recruitment start date

2012-05-21, 1391/03/01

Expected recruitment end date

2013-05-22, 1392/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

comparison of memantine and ritalin in the treatment of children with ADHD

Public title

comparison of Memantine and Methylphenidate in the treatment of children with ADHD

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: receiving DSM-IV-TR diagnostic criteria for ADHD; the age range of 6 to 11 years old; not using any psychiatric drugs at least 2 weeks before the research. Exclusion criteria: having mental retardation; having any psychiatric disorders except ODD; allergic history to Memantine; having serious disorder like heart disease; uncontrolled Seizure disorder; individuals with Systolic blood pressure above 125 mmHg or resting pulse under 60 or having above 115 beats per minute.

Age

From **6 years** old to **11 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: 40

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Tehran University of Medical Sciences

Street address

Qods street, Keshavarz Blvd, Tehran

City

Tehran

Postal code

Approval date

2012-04-08, 1391/01/20

Ethics committee reference number

17262

Health conditions studied

1

Description of health condition studied

attention deficiency hyperactivity disorder

ICD-10 code

F90.0

ICD-10 code description

Disturbance of activity and attention

Primary outcomes

1

Description

the ADHD symptoms

Timepoint

Baseline, third and sixth weeks after intervention

Method of measurement

ADHD Rating Scale, Clinical Global Impressions Severity

Secondary outcomes

1

Description

Side effects

Timepoint

Baseline, third and sixth weeks after intervention

Method of measurement

Side effects questionnaire

Intervention groups

1

Description

One group of patients are randomly assigned to the intervention group are treated with Memantine 10 mg. Therapeutic dosage of Memantine 10 mg is prescribed a tablet daily for the first week (half tablet in the morning at 8 o'clock, and half tablet at 14 o'clock) and 2 tablets are daily prescribed in the second week (one tablet in the morning at 8 o'clock, one tablet at 14 o'clock).

Category

Treatment - Drugs

2

Description

One group of patients are randomly assigned to receive methylphenidate in the control group. Methylphenidate 10 mg is prescribed for the first week, a daily tablet (half tablet in morning at 8 o'clock and half tablet at 14 o'clock); in the second week, two tablets are daily prescribed (one in the morning at 8 o'clock, one at 14 o'clock); if the weight is above 30 pounds, 3 tablets will be daily prescribed in the second week (one and a half tablet each morning at 8 o'clock, one and a half tablet at 14 o'clock)

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Roozbeh hospital

Full name of responsible person

Soleiman Mohammadzadeh

Street address

Roozbeh Hospital, South Kargar Avenue, after the Lashkar crossroads, Tehran, IRAN.

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Mrs karimi

Street address

Fifth floor, Qods street, Keshavarz Blvd, Tehran

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences, Psychiatry research center

Full name of responsible person

Soleiman Mohammadzadeh, MD

Position

Assistant specialist child and adolescent psychiatry

Other areas of specialty/work

Street address

Roozbeh Hospital, South Kargar Avenue, after the Lashkar crossroads, Tehran, IRAN

City

Tehran

Postal code

Phone

+98 21 5541 3540

Fax

Email

dr.mohammadzadeh86@gmail.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences, Psychiatry and Psychology Research Center

Full name of responsible person

Mohammad Reza Mohammadi

Position

MD

Other areas of specialty/work

Street address

Psychiatry and Psychology Research Center, Roozbeh Hospital, South Kargar Avenue, after the Lashkar crossroads, Tehran, IRAN.

City

Tehran

Postal code

Phone

+98 21 5541 3540

Fax

Email

mohammadimr@tums.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Psychiatry and Psychology Research Center

Full name of responsible person

Maryam Salmanian

Position

MS/Researcher

Other areas of specialty/work

Street address

City

Postal code

Phone

+98 21 5541 3540

Fax

Email

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty